Results 151 to 160 of about 9,065 (221)

Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy. [PDF]

Adv Ther
Rognoni C, Lorusso D, Costa F, Armeni P.
europepmc   +1 more source

Deciphering protein mutation-phenotype linkages from CRISPR-based tiling mutagenesis screens. [PDF]

Cell Syst
He W, Huang JW, Wang Y, Hayward SB, Leuzzi G, Fu R, Wang S, Vaitsiankova A, Chen Y, Bedford MT, Guerois R, Ciccia A, Xu H.   +12 more
europepmc   +1 more source

Review of open-source software for developing heterogeneous data management systems for bioinformatics applications. [PDF]

Bioinform Adv
Silva D, Moir M, Dunaiski M, Blanco N, Murtala-Ibrahim F, Baxter C, de Oliveira T, Xavier JS, INFORM Africa Research Study Group .   +8 more
europepmc   +1 more source

A novel ex vivo platform for functional evaluation of treatment responses in metastatic ovarian cancer. [PDF]

NPJ Precis Oncol
Valdivia A, Adefolaju A, Thang M, Stockwell C, Cuaboy LA, John C, Mann B, Satterlee A, Bae-Jump VL, Hingtgen S.   +9 more
europepmc   +1 more source

VectorSage: enhancing PubMed article retrieval with advanced semantic search. [PDF]

Bioinform Adv
Wijesekara Y, Brahma R, Lotfi M, Vollmer M, Kaderali L.   +4 more
europepmc   +1 more source

Web-based OLAP [PDF]

, 2010
Hsiao, Tim I-Hsuan
core  

Automated self-service cohort selection for large-scale population sciences and observational research: The California Teachers Study researcher platform. [PDF]

PLoS One
Lacey JV, Spielfogel ES, Benbow JL, Savage KE, Lin K, Anderson CAM, Clague-DeHart J, Duffy CN, Martinez ME, Park HL, Thompson CA, Wang SS, Chandra S.   +12 more
europepmc   +1 more source

Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. [PDF]

Cell Rep
Leesang TE, Brabson JP, Yap YS, Barbieri DA, Klimas AS, Pinzone J, Ahearn EL, Lam MQ, Lyon PD, Swirski A, Wolfe NB, Nakata Y, Dos Santos HG, Shiekhattar R, Morey L, Vlantis PI, Figueroa ME, Chandhok N, Beckedorff F, Telonis AG, Cimmino L.   +20 more
europepmc   +1 more source

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. [PDF]

J Clin Invest
Köcher S, Elsesy ME, Moustafa A, Mohammadi W, Perugachi Heinsohn A, Nagaraj Y, Oh-Hohenhorst SJ, Hahn J, Siebels B, Mair T, Burdak-Rothkamm S, Tennstedt P, Simon R, Lange T, Tilki D, Frenzel T, Maurer T, Petersen C, Schlüter H, Bokemeyer C, von Amsberg G, Rothkamm K, Mansour WY.   +22 more
europepmc   +1 more source

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. [PDF]

Neuro Oncol
Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, The S, Hu N, Valvo VM, Doherty R, Peterson E, Wang X, Venkataraman S, Agnihotri S, Venneti S, Wahl DR, Green MD, Lawrence TS, Koschmann C, Morgan MA, Zhang Q.   +20 more
europepmc   +1 more source